Oppenheimer & Co. Inc. Lowers Stock Holdings in Zoetis Inc. $ZTS

Oppenheimer & Co. Inc. reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 8.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,275 shares of the company’s stock after selling 11,310 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $8,356,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP grew its holdings in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the period. State Street Corp increased its stake in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after acquiring an additional 149,382 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Zoetis during the 4th quarter worth about $734,425,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $73.64 on Friday. The firm has a market capitalization of $30.43 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.31 and a beta of 0.74. Zoetis Inc. has a 1-year low of $71.45 and a 1-year high of $160.48. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The business’s 50-day simple moving average is $76.30 and its 200-day simple moving average is $99.01.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is currently 34.93%.

Analysts Set New Price Targets

Several research firms recently issued reports on ZTS. Stifel Nicolaus decreased their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Barclays dropped their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Finally, TD Cowen dropped their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Hold” and a consensus price target of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.